Skip to main content
. 2024 Jan 8;7:62. doi: 10.1038/s42003-023-05744-8

Fig. 2. Progression of kappa and lambda therapeutic antibodies into late-stage clinical trials, by year.

Fig. 2

Tracking the numbers of 100% sequence non-redundant κ and λ variable regions (Fvs) across post Phase-I sequence non-redundant clinical stage therapeutics (NR CSTs) from 1988 to 2023. The x-axis reflects the year in which each CST was granted a proposed International Non-proprietary Name (INN) by the World Health Organisation (WHO). Cumulative totals are shown through a stacked bar chart, while year-by-year totals are shown in the line graph. 2021–2023 are shown in dashed lines; these totals will likely change markedly once more therapeutics first reported in these years have had time to advance past Phase-I Clinical Trials.